| Identification | Back Directory | [Name]
Insulin-like Growth Factor-1 Receptor Inhibitor | [CAS]
468740-43-4 | [Synonyms]
CS-469
CS-0117
HY-10262
BMS-536924
BMS-536924, >=98%
BMS-536924 (CS0117
BMS 536924;BMS536924
BMS-536924 >=98% (HPLC)
BMS-536924(HY-10262, CS-0117)
Insulin-like Growth Factor-1 Receptor Inhibitor
Insulin-like Growth Factor-1 Receptor Inhibitor USP/EP/BP
BMS-536924
Insulin-like Growth Factor-1 Receptor Inhibitor
(S)-4-((2-(3-Chlorophenyl)-2-hydroxyethyl)amino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one
(S)-4-[2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-3-(4-methyl-6-morpholin-4-yl-1H-benzoimidazol-2-yl)-1H-pyridin-2-one
4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone
4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-(4-morpholinyl)-1H-benzimidazol-2-yl]- 2(1H)-pyridinone
2(1H)-Pyridinone, 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-
4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]aMino]-3-[7-Methyl-5-(4-Morpholinyl)-1H-benziMidazol-2-yl]-2(1H)-pyridinone BMS-536924 | [Molecular Formula]
C25H26ClN5O3 | [MDL Number]
MFCD14635360 | [MOL File]
468740-43-4.mol | [Molecular Weight]
479.959 |
| Chemical Properties | Back Directory | [Melting point ]
>206°C (dec.) | [density ]
1.44 | [storage temp. ]
Keep in dark place,Inert atmosphere,Store in freezer, under -20°C | [solubility ]
DMSO (Slightly) | [form ]
Solid | [pka]
10.40±0.10(Predicted) | [color ]
Light Yellow to Yellow | [CAS DataBase Reference]
468740-43-4 |
| Hazard Information | Back Directory | [Uses]
BMS 536924 is an inhibitor of insulin-like growth factor receptor (IGF1R) kinase and insulin receptor. BMS 536924 was reported to have antitumor activity. | [Definition]
ChEBI: 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-(4-morpholinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-pyridinone is a member of benzimidazoles. | [in vivo]
BMS-536924 (100 mg/kg; gavage; daily; for 35 days) causes regression of xenografts in vivo and an average reduction of 76% tumor volume after 2 weeks[2].
| Animal Model: | Athymic nude mice with CD8-IGF-IRMCF10A cells[2] | | Dosage: | 100 mg/kg | | Administration: | Gavage; daily; for 35 days | | Result: | Caused an average reduction of 76% tumor volume after 2 weeks.
|
| [storage]
Store at -20°C |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Telephone: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15748/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|